Text Message Support for Opioid Use Disorder and Chronic Pain
This study is testing if daily text messages can help people taking medications like methadone, buprenorphine, or Suboxone/Subutex for Opioid Use Disorder (OUD) and chronic pain. You would receive daily medication reminders and up to six mindfulness text messages for four weeks. Researchers want to see if these messages improve how well you take your medication and help manage cravings, pain, and withdrawal symptoms. They are also looking at how much people engage with the mindfulness messages. The study plans to enroll 60 participants who are 18 or older, have a cellphone and internet, and are within six months of starting or restarting their OUD medication. The study's status is currently unclear.
- Study design
- This interventional study plans to enroll 60 participants. You would be randomized daily to receive a different number of mindfulness messages.
- What's involved
- You would receive daily medication reminder text messages for at least 24 weeks and up to six daily mindfulness text messages for 4 weeks. You will complete surveys at the start, and at 1, 2, and 6 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for 24 weeks (6 months) after the study begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Opioid Adherence and Support Through Innovative Texting Strategies
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Mindfulness text intervention engagementMeasured daily for four weeks
Participants reply to a binary ("Today, did you think about or use any suggestion from the OASIS Study text messages?") and continuous ("How much did you think about or use any suggestion from the OASIS text messages?; response range: 0=not at all, 10=very much) question about intervention engagement. They also indicate how much they believe the texting helped them manage their pain, urge to use opioids, remember to take their medication, and manage their withdrawal symptoms (response range: 0=not at all, 10=very much).
- Intervention acceptabilityFrom baseline to 24-week (i.e., 6-month) follow-up
Responding to EMA on 25%, 50%, and 75% of days will indicate a low, medium, and high level of acceptability, respectively. An adapted version of a message fatigue measure and a scale of intervention engagement will be used with a response greater than 3 (1 to 5 scales) on each item representing at least some satisfaction with treatment and will serve as the benchmark for acceptability.
- Intervention feasibilityFrom baseline to 24-week (i.e., 6-month) follow-up
Feasibility benchmarks are assessed continually thoughout the study, beginning with the recruitment rate of eligible participants (≥50% of potential participants) and continuing as quantified by retention at 4 weeks (≥75%), 8 weeks (≥65%), and 24 weeks (≥55%). These data are all proportions and are collected as continuous measures of feasibility as quantified by participant engagement.
- Medication adherenceFrom baseline to 24-week (6-month) follow-up
Medication for opioid use disorder (MOUD) adherence rate is assessed within individuals. Within-subject adherence will be quantified as ≥80% of days taking MOUD. Six-month between-subject retention rates will be classified using the following ranges based on results from prior studies of buprenorphine and methadone adherence. Buprenorphine: 25% or less = low, 25 to 40% = moderate, and 40% or greater = high. Methadone: 40% of less = low, 40 to 50% = moderate, 50% or greater = high.